Home » Stocks » CytRx Corporation

CytRx Corporation (CYTR)

Stock Price: $0.580 USD 0.010 (1.81%)
Updated Oct 20, 2020 2:16 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 19.52M
Revenue (ttm) n/a
Net Income (ttm) -6.98M
Shares Out 33.64M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $0.580
Previous Close $0.570
Change ($) 0.010
Change (%) 1.81%
Day's Open 0.570
Day's Range 0.561 - 0.660
Day's Volume 89,044
52-Week Range 0.23 - 0.847

More Stats

Market Cap 19.52M
Enterprise Value 5.61M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 33.64M
Float 28.01M
EPS (basic) -0.20
EPS (diluted) -0.21
FCF / Share -0.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 294,308
Short Ratio 1.96
Short % of Float 1.05%
Beta 1.77
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.72
Revenue n/a
Operating Income -7.20M
Net Income -6.98M
Free Cash Flow -4.79M
Net Cash 13.91M
Net Cash / Share 0.41
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.29%
ROE -44.96%
ROIC -397.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.50*
Low
4.50
Current: $0.580
High
4.50
Target: 4.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-0.250.100.200.100.100.300.100.250.10
Revenue Growth-150%-50%100%0%-66.67%200%-60%150%-
Gross Profit-0.250.100.200.100.100.300.100.250.10
Operating Income-7.86-8.25-28.36-52.26-63.28-49.61-27.59-21.05-22.65-16.75
Net Income-7.16-12.71-34.99-50.77-58.59-30.12-47.49-17.96-14.420.41
Shares Outstanding33.2630.9524.0413.5110.089.065.483.832.992.61
Earnings Per Share-0.22-0.41-1.46-3.78-5.82-3.30-8.64-4.68-4.800.18
Operating Cash Flow-5.72-10.87-27.10-49.85-47.58-40.56-23.75-19.04-16.67-14.54
Capital Expenditures0.48-0.01-0.13-1.02-0.33-0.96-0.04-0.14-0.05-0.32
Free Cash Flow-5.24-10.88-27.24-50.87-47.91-41.51-23.79-19.19-16.72-14.86
Cash & Equivalents16.1321.3737.5056.9657.3077.8438.5738.3436.0526.89
Total Debt0.07-10.6023.97------
Net Cash / Debt16.0621.3726.9032.9957.3077.8438.5738.3436.0526.89
Assets17.2622.9348.3562.7767.0285.6941.5040.2337.8536.70
Liabilities2.052.5630.2037.9922.9517.7830.8410.0713.606.13
Book Value15.2020.3618.1524.7844.0867.9110.6630.1724.2530.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CytRx Corporation
Country United States
Employees 4
CEO Steven A. Kriegsman

Stock Information

Ticker Symbol CYTR
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: CYTR
IPO Date November 10, 1986

Description

CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.